Baader Bank Aktiengesellschaft Acquires 2,422 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Key Points

• Baader Bank Aktiengesellschaft increased its holdings in BioNTech by 1.7%, now owning 142,822 shares, which constitutes 1.0% of its investment portfolio.
• Several other large investors have recently acquired stakes in BioNTech, indicating growing interest from institutional investors, with 15.52% of the stock owned by such entities.
• BioNTech's stock has seen a slight decline of 1.3%, trading at $110.05, with a market capitalization of $26.45 billion.

Baader Bank Aktiengesellschaft lifted its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 1.7% in the first quarter, according to its most recent filing with the SEC. The firm owned 142,822 shares of the company's stock after acquiring an additional 2,422 shares during the period. BioNTech makes up about 1.0% of Baader Bank Aktiengesellschaft's investment portfolio, making the stock its 14th biggest position. Baader Bank Aktiengesellschaft owned 0.06% of BioNTech worth $12,937,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Banque Cantonale Vaudoise bought a new position in BioNTech during the 1st quarter valued at about $36,000. Allianz SE bought a new position in BioNTech during the 4th quarter valued at about $90,000. Goodman Advisory Group LLC bought a new position in BioNTech during the 1st quarter valued at about $105,000. Tower Research Capital LLC TRC lifted its holdings in BioNTech by 61.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after purchasing an additional 713 shares during the last quarter. Finally, Probity Advisors Inc. lifted its holdings in BioNTech by 8.5% during the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock valued at $224,000 after purchasing an additional 154 shares during the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Trading Down 0.1%

NASDAQ BNTX traded down $0.16 during trading on Friday, reaching $107.34. 840,683 shares of the stock traded hands, compared to its average volume of 952,607. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The stock's 50-day moving average price is $107.94 and its 200 day moving average price is $106.31. The firm has a market cap of $25.80 billion, a price-to-earnings ratio of -31.57 and a beta of 1.29.

Analyst Ratings Changes

Several equities research analysts have weighed in on BNTX shares. Leerink Partners set a $112.00 price objective on shares of BioNTech in a research report on Monday, June 2nd. JPMorgan Chase & Co. lowered their price objective on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. Truist Financial restated a "buy" rating and issued a $155.00 price objective (up previously from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. HC Wainwright restated a "buy" rating and issued a $138.00 price objective on shares of BioNTech in a research report on Wednesday, June 25th. Finally, Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, BioNTech has a consensus rating of "Moderate Buy" and a consensus target price of $136.58.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.